MESALAMINE (mesalamine) by Viatris (2) is understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Approved for mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg, ulcerative colitis. First approved in 2024.
Drug data last refreshed Yesterday
understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with ulcerative colitis, and it is possible that mesalamine…
Aminosalicylate
Worked on MESALAMINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)